Presenter: Nicholas J. Maragakis, M.D., Johns Hopkins University
The development of biomarkers for understanding ALS progression and for establishing therapeutic target engagement is at a critical stage. As new therapies are being studied, the identification of specific targets of interest can only be imagined by analyzing the cerebrospinal fluid—a window into the ALS brain. In this webinar, we will discuss the procedure for lumbar puncture and its rationale. A discussion about CSF biomarker development will follow.
